

Centers for Medicare & Medicaid Services
Office of Research, Development, and Information
Medicare Demonstrations Program Group

October 2006



Legislative Mandate

Section 302(b) of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA)



Legislative Requirements

Conduct a demonstration that applies competitive acquisition to clinical laboratory services that would otherwise be paid under the **Medicare Part B (fee for service)** clinical laboratory fee schedule



MMA Requirements

- Exclude Pap smears and colorectal cancer screening tests
- Exclude "face to face encounter"
- Include CLIA requirements
- Select multiple winners
- Achieve budget savings
- Report to Congress



Where we are as of September 2006

This presentation is a summary of the proposed demonstration design elements



Where we are going

- OMB approval
- CMS announcement
- Bidders package
- Bidders conference
- Bids due
- Applications evaluated



Proposed **Bidders Package**

- Background and Objectives
- Structure of the Demonstration
- Bidding Guidelines and Components
- Guidelines for Bid Price Table
- Bid Evaluation
- Outreach and Education
- Terms and Conditions of Participation
- Glossary



Proposed **Bidders Conference**

- Bidders Package
- Questions & Answers
- Held in demonstration area or competitive bid area ("CBA")
- CMS and research contractor onsite



Proposed Structure of the Demonstration

The Medicare Part B clinical laboratory fee schedule

 Beneficiaries who live in the competitive bid area ("CBA")



"Face to Face" exclusion

Intent of Congress

 NOT based on phlebotomy or specimen collection site



A "Face to Face" encounter

<u>ls</u>

- POL patient
- Hospital inpatient
- Hospital outpatient

Is Not

- Independent
- Hospital nonpatient
- POL nonpatient



Proposed **Demonstration Tests**

Tests paid under the Medicare Part B Clinical Laboratory Fee Schedule

 Except: pap smears, colorectal cancer screening tests and new tests added to the Medicare Part B Clinical Laboratory Fee Schedule during the course of the demonstration



Proposed **Demonstration Tests**

 Tests provided to beneficiaries enrolled in the traditional fee-forservice Medicare program whose permanent residence is in the CBA

 Tests provided by independent clinical laboratories, hospital or physician office laboratories for non-patients



Proposed Required Bidders

Firms with \$100,000 or more in demonstration test annual Medicare payments in the CBA



Proposed Small Laboratory Provision

- Firms with < \$100,000 in demonstration test annual Medicare payments in the CBA
- NOT required to bid
- Paid the competitively bid fee schedule for demonstration tests provided to beneficiaries residing in the CBA
- Annual payments capped



Proposed Winners & Non-winners

Laboratories that are required to bid and choose not to bid will be ineligible for Medicare Part B reimbursement for demonstration tests provided to beneficiaries residing in the CBA



Proposed Winners & Non-winners

Laboratories that bid and do not win will be ineligible for Medicare reimbursement for demonstration tests provided to beneficiaries residing in the CBA



Proposed **Demonstration Tests Fees**

Laboratories that bid and win will be paid under one competitively set demonstration Medicare Part B clinical laboratory fee schedule for demonstration tests provided to beneficiaries residing within the CBA



Proposed Non-demo Tests Fees

 Fees for non-demonstration tests will continue to be paid under the existing fee schedule

 Fees for non-demonstration tests will be unaffected by a laboratory's participation or non-participation in the demonstration project



Proposed **Bid Components**

- Ownership
- Quality
- Financial stability
- Demonstration test bid price
- Capacity and geographic coverage
- Subcontracting and referrals
- Anti-Trust laws



Proposed Capacity and Geographic Service Area

Ensure beneficiary access

 Component of multi-dimensional criteria for the selection of multiple winners



Proposed **Subcontracting & Referrals**

How bidders will provide tests not performed in-house

CLIA certified laboratory



Proposed Antitrust Laws

- Collusion and anti-competitive behavior are prohibited
- Includes subcontracting and referral business arrangements
- Federal Trade Commission (FTC) and Department of Justice (DOJ) have jurisdiction



Proposed **Demonstration Sites**

- 2 demonstration sites / CBA's
- Each site will last 3 years
- Staggered start
- Metropolitan Statistical Areas (MSA) used to define CBA



Proposed Site Selection Objectives

- Potential Medicare program savings
- Administrative feasibility
- CBA is representative
- Results are generalizable



Proposed Site Selection Criteria

- MSA
- Within a single State
- Moderately large beneficiary populations
- Moderate Medicare managed care penetration
- 22 MSAs meet the criteria



Proposed Quality -Protective Design Elements

- CLIA regulations
- Key criterion in selection of winners
- Additional quality indicators
- Designated QA manager
- Competition between winners
- Marketing by winning laboratories

Proposed Access – Protective Design Elements

- CBA's selected to ensure sufficient numbers of laboratories
- Capacity and geographic coverage considered when selecting winners
- Multiple winners
- Additional measures of access



For More Information

Project webpage:

http://www.cms.hhs.gov/DemoProjects EvalRpts/MD/itemdetail.asp?itemID=C MS023785

Dedicated email box:

lab_bid_demo@cms.hhs.gov